BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency...

April 07, 2026 | News

Syneron Bio Secures Series B Financing To Advance Macrocyclic Peptide Discovery Platform And Clinical Pipeline

Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on Marc...

April 06, 2026 | News

CellCarta And Pillar Biosciences Partner To Accelerate NGS Tumor Profiling For Biomarker Driven Oncology Trials

CellCarta, a global provider of precision medicine laboratory services for drug development, and Pillar Biosciences, a leader in NGS-based oncology molecul...

April 03, 2026 | News

Abbisko Therapeutics Secures EMA Orphan Drug Status For Irpagratinib In Liver Cancer

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral...

April 02, 2026 | News

Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company w...

March 30, 2026 | News

Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that it has received clearance from the Center for Drug Evaluation (CDE) of China's ...

March 26, 2026 | News

Alphamab Oncology Initiates Phase III Study Of Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...

March 25, 2026 | News

Prestige Biopharma Reports Phase 3 Success For HD204 Demonstrating Clinical Equivalence In Advanced NSCLC

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung can...

March 25, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Alphamab Oncology Doses First Patient In Global Phase I Trial Of First PD L1 VEGFR2 Bispecific ADC

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101...

March 18, 2026 | News

Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...

March 16, 2026 | News

Vaxcellbio And Reber Genetics Form Strategic Partnership To Expand Companion Animal Immunotherapy Across Asia

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) wi...

March 12, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Servier To Acquire Day One Biopharmaceuticals For $2.5 Billion To Strengthen Rare Oncology Pipeline

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with...

March 09, 2026 | News

Stay Connected